skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children

Human Herpesvirus 8 Disease

(Last updated:11/6/2013; last reviewed:11/6/2013)

Panel's Recommendations

Panel’s Recommendations

  • Effective suppression of HIV replication with combination antiretroviral therapy (cART) is recommended to reduce the risk of human herpesvirus 8- (HHV-8)—associated Kaposi sarcoma (AIII). 
  • Routine testing to identify HHV-8—seropositive, HIV-infected patients is not recommended (BIII).
  • Effective suppression of HIV replication with cART is recommended for all patients with evidence of active KS and other human herpesvirus 8-associated malignant lymphoproliferative disorders (AIII).
  • The use of intravenous ganciclovir or oral valganciclovir is recommended for treatment of HHV-8—associated multicentric Castleman disease (BIII) and may be a useful adjunct for treating HHV-8-associated primary effusion lymphoma (BIII). 
  • Appropriate chemotherapy, in combination with potent cART, should be considered for patients with visceral KS or primary effusion lymphoma (BII*).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials in children with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents


Human herpesvirus 8 (HHV-8) is a transmissible DNA virus, with similarities in DNA structure to Epstein-Barr virus. HHV-8 has been causally linked to all forms of Kaposi sarcoma (KS) (HIV-related and endemic) and with two rare neoplastic conditions usually associated with HIV infection: body cavity-based lymphoma, also known as primary effusion lymphoma (a B-cell lymphoma that typically arises in body cavities such as the pleural space) and multicentric Castleman disease (non-cancerous tumors that may develop in lymph nodes in a single site or in multiple sites throughout the body). The exact mechanism by which HHV-8 infection leads to neoplastic disease has not been fully elucidated, but seroconversion to HHV-8 antibody positivity virtually always precedes development of the tumors.1 Higher plasma HHV-8 DNA titers are associated with increased risk of KS.2

The prevalence of antibodies to HHV-8 varies widely with age and geography. In the United States and Europe, 1% to 3% of the general adult population is seropositive, with higher rates (8%) among men who have sex with men (MSM).3 Among other adult men in the general population, HHV-8-seropositivity was marginally associated with duration of heterosexual activity and positively associated with the number of lifetime sex partners and co-infection with hepatitis B virus and herpes simplex virus type 2 viruses; none of these were significantly associated with risk for women. In contrast, the adult seropositivity rate in Mediterranean countries ranges from 10 to 25%. In areas where HHV-8 is endemic, such as eastern and central Sub-Saharan Africa, HHV-8 seropositivity rates as high as 80% have been reported in adults.4-8 

HHV-8 is transmitted through oral and genital secretions. Immunocompetent HHV-8-infected adults frequently shed HHV-8 in their oropharyngeal secretions, with viral DNA detected in saliva on 22% of test days.9 In areas where HHV-8 infection is endemic, the seroprevalence increases quickly during the first 5 years of life (especially when other family members are HHV-8-positive), then plateaus until adolescence and young adult years. In studies from rural Tanzania and Uganda, the rate of positivity for HHV-8 was 3.7% to 16% among infants, 58% among children aged 4 to 5 years, and 49% to 89% among adults aged >45 years.10,11 The seroprevalence among infants and children increased with the number of HHV-8-positive parents and siblings in the home, indicating non-sexual transmission for pre-pubertal children, with a limited role for perinatal transmission.10-17

In the United States, among a cohort of HIV-infected and at-risk HIV-negative adolescents with a median age of 19 years, 11.2% were HHV-8 seropositive.18 The highest rates were in adolescent HIV-infected males reporting sex with males (23%). Seropositivity was associated with HIV infection, MSM, a history of syphilis, and injection-drug use.18,19

HHV-8 can be transmitted through exposure to infected blood. Adult injection-drug users have an increased rate of HHV-8 positivity.18,19 In addition, recent evidence suggests that HHV-8 may be transmitted through blood product transfusions. In one study in an area of Uganda with a high incidence of HHV-8-seropositivity, the excess risk of acquiring HHV-8 through transfusion was nearly 3% when recipients of HHV-8 antibody-positive blood were compared with those receiving HHV-8 antibody-negative blood.20

A small study suggested that maternal HHV-8 infection might increase risk for perinatal transmission of HIV, although no evidence of mother-to-child transmission of HHV-8 infection was identified among HIV-infected infants.15 Women coinfected with HHV-8 and HIV had increases in both HHV-8 and HIV viral load in serum and/or cervical fluid during pregnancy, when compared to their pre-pregnancy levels and to HHV-8 and HIV coinfected, non-pregnant women.21

For HIV-infected individuals, coinfection with HHV-8 places them at risk of KS. The risk is highest in adults (compared to children). Before the advent of combination antiretroviral therapy (cART), the overall incidence of KS in HIV-infected adults was as high as 20%. However, the rate among children was low. In the United States and England, KS represented <1% of pediatric AIDS-defining illnesses. The risk of KS is also highest in individuals with severe immunodeficiency. KS, primary effusion lymphoma, and multicentric Castleman disease can occur at any CD4 T lymphocyte (CD4) count level, but they are described most often in HIV-infected patients with more advanced immunosuppression (CD4 cell count <200 cells/mm3 in adults). 

The incidence of KS appeared to decline even before the widespread use of cART. The reason is unclear but may have been related to the use of other antiviral agents, such as those used to treat cytomegalovirus (CMV) (i.e., foscarnet, ganciclovir, and cidofovir), which may inhibit HHV-8.22-28 With the advent of earlier and more aggressive cART, the incidence of KS in adults has continued to decrease. In a well-characterized, HIV-infected adult cohort, the incidence fell from 33/1,000 person-years before 1996, to 5.1/1,000 person-years in 1996 to 1998 and 1.4/1,000 since 1999. Of note, the risk of KS decreased sharply after the first few months on cART and remained low for 7 to 10 years after the initiation of antiretroviral therapy.29,30

Although KS occurs primarily in adults, the incidence in children has increased substantially as a result of the HIV pandemic, particularly in Africa and because of frequent use of immunosuppressive drugs. One series reported a 40-fold increase in incidence of childhood KS in Uganda in the era of AIDS;31 a 30-fold increase was also noted recently in South Africa,32 where KS represented 5% of pediatric cancers. In a cohort of 6,530 HIV-infected children in Uganda, 1.7% were found to have a malignancy, 91% of which were KS.33

Clinical Manifestations

A febrile illness with mild respiratory symptoms and a maculopapular rash and a mononucleosis-like illness have been associated with primary infection in young, immunocompetent children.34,35 A similar self-limited illness has been described in adults with primary infection. Evidence suggests more significant symptomatology in immunodeficient adults with primary infection, including reports of fever, arthralgia, splenomegaly, and bone marrow suppression.36,37 

KS presentation varies widely, but most patients have non-tender, purplish, indurated skin lesions. Intraoral lesions can be seen and visceral dissemination can occur, occasionally without skin lesions. Multicentric Castleman disease presents with generalized adenopathy and fever and may progress to multiorgan failure. Primary effusion lymphoma presents with symptoms related to fluid accumulation in the pleural or pericardial space or with abdominal distention. In South Africa32 the average age at the time of diagnosis of KS in HIV-infected children was 72 months; median CD4 percentage and count at the time of diagnosis were 12% and 440 cells/μL, respectively. Just over half presented with skin lesions; 30% had adenopathy and 25% had oral lesions. In a study in Mozambique, biopsy-proven KS was observed in 32 HIV-infected children (0.8% of all HIV-infected children seen between 2003–2008); mean age was 8.3 years and median CD4 percentage was 16%.38 KS affected the lymph glands in 5 children, the skin in 10 children, and was mixed in 13 children (both cutaneous and nodal in 12 children and cutaneous and lung in 1 child).38 

Making the Diagnosis

Laboratory diagnosis of HHV-8 infection is most commonly based on serologic assays, such as immunofluorescence, enzyme-linked immunosorbent assay, and Western blot. However, without a standard for diagnosing HHV-8 infection, these tests range in sensitivity from 80% to ≥90% and interassay agreement is poor.39 Combination assays containing both lytic and late-phase antigens may improve detection rates. Nucleic acid-based tests, such as in situ DNA hybridization and polymerase chain reaction (PCR), are important for tissue diagnosis. Although these tests have high levels of sensitivity, specificity and reproducibility are highly variable. Only 40% to 60% of patients with proven KS will have detectable HHV-8 DNA in their blood by PCR.

Laboratory diagnosis of KS is based on histologic examination of affected tissues.

Prevention Recommendations

Preventing Exposure

Routine testing of children and adults for HHV-8 is not recommended; therefore, the serostatus of HIV-infected patients usually is unknown. Although the efficacy of condoms in preventing HHV-8 exposure has not been established, HIV-infected patients should use male latex condoms correctly and consistently during sexual intercourse to reduce exposure to sexually transmitted pathogens. HIV-infected injection-drug users should be counseled not to share drug-injection equipment, even if both users are already HIV-infected, because of the risk of becoming infected with HHV-8 or other blood-borne pathogens. Adolescents who are diagnosed with KS should be counseled about the possibility of transmitting HHV-8 to their sexual contacts through intercourse and, possibly, kissing.

In the future, HHV-8 testing of donated blood products before use in immunodeficient patients may be considered. In addition, routine use of leukocyte reduction for red cell transfusions may lower the transmission risk.

Infants can acquire HHV-8 perinatally or through contact with infected family members and playmates. No effective intervention is known to prevent childhood acquisition of HHV-8, although avoidance of salivary exposure (e.g, via pre-mastication of food) may theoretically prevent transmission.

Preventing First Episode of Disease

The use of cART with suppression of HIV replication has markedly decreased the incidence of KS in HIV-infected adults (AIII). Routine testing to identify HHV-8-seropositive, HIV-infected individuals is not recommended (BIII). Although several antiviral agents (namely, ganciclovir, foscarnet, and cidofovir) inhibit HHV-8 replication in vitro, no data exist on their use to prevent KS in patients who are HIV/HHV-8 coinfected.

Treatment Recommendations

Treating Disease

Specific treatment recommendations are not included in this report because the HIV-related clinical entities associated with HHV-8, such as KS and Castleman disease, are oncologic and traditionally have been treated with cytotoxic chemotherapy. However, in HIV-infected patients with KS, effective suppression of HIV replication with cART may prevent KS progression or occurrence of new lesions. Therefore, cART is recommended for all HIV-infected patients with evidence of active KS and other HHV-8-associated malignant lymphoproliferative disorders (AIII). Appropriate chemotherapy, in combination with potent cART, should be considered for patients with visceral KS or primary effusion lymphoma (BII*). A retrospective analysis of 28 HIV-infected children in Mozambique treated with cART and 6 cycles of monthly paclitaxel showed that treatment was well-tolerated and resulted in complete and sustained remission of KS in 19 children.38 

In HIV-infected adults with KS, HHV-8 cellular viremia and higher viral load have been associated with disease progression.40 Treatment with specific antiviral agents that have in vitro activity against the lytic but not latent phase of HHV-8 (e.g., ganciclovir, foscarnet, cidofovir), has not been widely studied. No therapeutic effect was noted when oral valganciclovir was given to five HIV-negative adults with KS.41 In addition, the vast majority of infected cells are not undergoing lytic replication, and anti-herpesvirus medications have had little or no effect on established KS or HHV-8 cellular viremia. Studies are under way of methods that induce lytic replication or attack the episomal (latent) HHV-8 genome.42,43

In contrast to KS, in Castleman disease, many of the cells support lytic replication of HHV-8, and treatment with anti-herpesvirus drugs has led to substantial clinical improvement in some studies.43 IV ganciclovir or oral valganciclovir is recommended for treating multicentric Castleman disease (BIII)44 and may be a useful adjunct for treating primary effusion lymphoma (BIII).45,46 

Monitoring and Adverse Events (Including IRIS)

Rapid progression of KS after initiation of cART and after a change from a failing regimen to a more potent one has been reported, representing immune reconstitution inflammatory syndrome (IRIS) associated with immunologic improvement. IRIS-related progression of KS usually appeared within 8 weeks after start of a potent cART regimen. Most patients experienced rapid progression of cutaneous lesions; however, sudden worsening of pulmonary KS, with resultant deaths, was reported in at least 4 patients. All reported fatalities were linked to pulmonary KS. In most cases, cART was continued with stabilization and then regression of lesions. In more severe cases, especially those involving visceral lesions, chemotherapy was instituted, and in combination with cART, led to regression of the KS.47,48 

For patients with disease manifestations of HHV-8 infection who are treated with ganciclovir or valganciclovir, refer to the chapter on CMV infections (Monitoring and Adverse Events) for information on treatment-associated adverse events.

Managing Treatment Failure

No recommendations exist for management of treatment failure.

Preventing Recurrence

Effective suppression of HIV replication with cART in HIV-infected patients with KS may prevent KS progression or occurrence of new lesions and is recommended for all individuals with evidence of active KS and other HHV-8-associated malignant lymphoproliferative disorders (AIII).

Discontinuing Secondary Prophylaxis

Not applicable.


  1. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med. Jul 25 1996;335(4):233-241. Available at
  2. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet. Sep 28 1996;348(9031):858-861. Available at
  3. Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. Jul 15 2007;196(2):199-207. Available at
  4. Whitby D, Smith NA, Matthews S, et al. Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis. Jan 1999;179(1):234-236. Available at
  5. Goedert JJ, Kedes DH, Ganem D. Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA. Lancet. May 10 1997;349(9062):1368. Available at
  6. Huang LM, Huang SY, Chen MY, et al. Geographical differences in human herpesvirus 8 seroepidemiology: a survey of 1,201 individuals in Asia. J Med Virol. Mar 2000;60(3):290-293. Available at
  7. Serraino D, Locatelli M, Songini M, et al. Human herpes virus-8 infection among pregnant women and their children: results from the Sardinia-IDDM Study 2. Int J Cancer. Mar 1 2001;91(5):740-741. Available at
  8. Martin JN. The epidemiology of KSHV and its association with malignant disease. 2007. Available at
  9. Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis. Jan 1 2007;195(1):30-36. Available at
  10. Butler LM, Were WA, Balinandi S, et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis. Mar 1 2011;203(5):625-634. Available at
  11. Mbulaiteye SM, Pfeiffer RM, Whitby D, Brubaker GR, Shao J, Biggar RJ. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis. Jun 1 2003;187(11):1780-1785. Available at
  12. He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. J Infect Dis. Dec 1998;178(6):1787-1790. Available at
  13. Gessain A, Mauclere P, van Beveren M, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer. Apr 12 1999;81(2):189-192. Available at
  14. Sitas F, Newton R, Boshoff C. Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med. Jun 17 1999;340(24):1923. Available at
  15. Calabro ML, Gasperini P, Barbierato M, et al. A search for human herpesvirus 8 (HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. Int J Cancer. Jan 15 2000;85(2):296-297. Available at
  16. Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. Sep 23 2000;356(9235):1062-1065. Available at
  17. Malope BI, Pfeiffer RM, Mbisa G, et al. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr. Mar 1 2007;44(3):351-355. Available at
  18. Casper C, Meier AS, Wald A, Morrow RA, Corey L, Moscicki AB. Human herpesvirus 8 infection among adolescents in the REACH cohort. Arch Pediatr Adolesc Med. Sep 2006;160(9):937-942. Available at
  19. Cannon MJ, Dollard SC, Smith DK, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. Mar 1 2001;344(9):637-643. Available at
  20. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. Sep 28 2006;355(13):1331-1338. Available at
  21. Lisco A, Barbierato M, Fiore JR, et al. Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women. J Clin Microbiol. Nov 2006;44(11):3863-3871. Available at
  22. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. Jun 1996;173(6):1477-1480. Available at
  23. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS. Sep 1996;10(10):1101-1105. Available at
  24. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol. Jun 1999;73(6):4786-4793. Available at
  25. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother. Dec 1997;41(12):2754-2756. Available at
  26. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. May 1 1997;99(9):2082-2086. Available at
  27. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. Jan 1 1999;20(1):34-38. Available at
  28. Cannon MJ, Laney AS, Pellett PE. Human herpesvirus 8: current issues. Clin Infect Dis. Jul 1 2003;37(1):82-87. Available at
  29. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. Sep 2 2008;99(5):800-804. Available at
  30. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. Dec 15 1999;282(23):2220-2226. Available at
  31. Ziegler JL, Katongole-Mbidde E. Kaposi's sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer. Jan 17 1996;65(2):200-203. Available at
  32. Stefan DC, Stones DK, Wainwright L, Newton R. Kaposi sarcoma in South African children. Pediatr Blood Cancer. Mar 2011;56(3):392-396. Available at
  33. Tukei VJ, Kekitiinwa A, Beasley RP. Prevalence and outcome of HIV-associated malignancies among children. AIDS. Sep 10 2011;25(14):1789-1793. Available at
  34. Chen RL, Lin JC, Wang PJ, Lee CP, Hsu YH. Human herpesvirus 8-related childhood mononucleosis: a series of three cases. Pediatr Infect Dis J. Jul 2004;23(7):671-674. Available at
  35. Andreoni M, Sarmati L, Nicastri E, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA. Mar 13 2002;287(10):1295-1300. Available at
  36. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. Nov 9 2000;343(19):1378-1385. Available at
  37. Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation. Jul 15 2002;74(1):131-132. Available at
  38. Vaz P, Macassa E, Jani I, et al. Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected Mozambican children with antiretroviral drugs and chemotherapy. Pediatr Infect Dis J. Oct 2011;30(10):891-893. Available at
  39. Bhaduri-McIntosh S. Human herpesvirus-8: clinical features of an emerging viral pathogen. Pediatr Infect Dis J. Jan 2005;24(1):81-82. Available at
  40. Laney AS, Cannon MJ, Jaffe HW, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS. Jul 31 2007;21(12):1541-1545. Available at
  41. Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis. Apr 15 2011;203(8):1082-1086. Available at
  42. Anderson LA, Goedert JJ. Tumor markers and treatments for Kaposi sarcoma. AIDS. Jul 31 2007;21(12):1637-1639. Available at
  43. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol. Sep 2005;17(5):447-455. Available at
  44. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. Mar 1 2004;103(5):1632-1634. Available at
  45. Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis. Jun 15 2002;34(12):1660-1662. Available at
  46. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS. Jul 13 2006;20(11):1567-1569. Available at
  47. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. Oct 2005;19(10):635-644. Available at
  48. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. Aug 1 2005;23(22):5224-5228. Available at